Similar articles

• Consequence of therapy discontinuation in bisphosphonate-associated osteonecrosis of the jaws.

  Gallego L, Junquera L. Gallego L, et al. Br J Oral Maxillofac Surg. 2009 Jan;47(1):67-8. doi: 10.1016/j.bjoms.2008.05.011. Epub 2008 Jul 17. Br J Oral Maxillofac Surg. 2009. PMID: 18639371
• Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report.

  Merigo E, Manfredi M, Meleti M, Corradi D, Vescovi P. Merigo E, et al. J Oral Pathol Med. 2005 Nov;34(10):613-7. doi: 10.1111/j.1600-0714.2005.00351.x. J Oral Pathol Med. 2005. PMID: 16202082
• Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.

  Grewal VS, Fayans EP. Grewal VS, et al. Todays FDA. 2008 Aug;20(8):38-41, 43-6. Todays FDA. 2008. PMID: 18767452
• Bisphosphonate-associated osteonecrosis of the jaws. Report of a case and literature review.

  Leite AF, Figueiredo PT, Melo NS, Acevedo AC, Cavalcanti MG, Paula LM, Paula AP, Guerra EN. Leite AF, et al. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Jul;102(1):14-21. doi: 10.1016/j.tripleo.2005.10.045. Epub 2006 Mar 20. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006. PMID: 16831667 Review.
• Bisphosphonate-induced osteonecrosis of the jaws: a case report and literature review.

  Tsai WS, Haghighi K, Placa SJ. Tsai WS, et al. Gen Dent. 2006 May-Jun;54(3):215-9; quiz 220-2. Gen Dent. 2006. PMID: 16776417 Review.